JLJoel López-Matías

Joel López-Matías

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joel López-Matías has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Karen Cruz-Acevedo

    Research Centre-Faculty of Medicine, National Autonomous University of Mexico-Benito Juárez Autonomous University of Oaxaca, Oaxaca, Mexico

    1 shared publication
  • Eduardo L. Pérez-Campos

    National Technological of Mexico, Technological Institute of Oaxaca, Oaxaca, Mexico

    1 shared publication
  • Laura Pérez-Campos Mayoral

    Centro de Investigación Facultad de Medicina UNAM-UABJO, Facultad de Medicina y Cirugía, Universidad Autónoma “Benito Juárez” de Oaxaca, Oaxaca 68020, Mexico

    1 shared publication
  • María Teresa Hernández-Huerta

    Secretariat of Science, Humanities, Technology and Innovation SECIHTI, Faculty of Medicine, Benito Juárez Autonomous University of Oaxaca, Oaxaca, Mexico

    1 shared publication
  • Miguel Cruz-Reyes

    Internal Medicine Department, General Hospital Dr. “Aurelio Valdivieso” IMSS-Bienestar, Oaxaca, Mexico

    1 shared publication
  • Víctor Cruz-Hernández

    División de Medicina Interna, Hospital General “Dr. Aurelio Valdivieso”, Instituto Mexicano del Seguro Social para el Bienestar, Oaxaca 68050, Mexico

    1 shared publication

Latest Publications

  • Open Access

    A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine

    by Ana Karen Cruz-Acevedo, Eduardo L. Pérez-Campos, María Teresa Hernández-Huerta, Miguel Cruz-Reyes, Joel López-Matías, Laura Pérez-Campos Mayoral, Víctor Cruz-Hernández

    Chronic eosinophilic leukemia (CEL) belongs to the group of chronic myeloproliferative neoplasms characterized by the persistence of an absolute eosinophil count (AEC) > 1.5 × 10 9 /L for 1–6 months and is accompanied by organ damage. The new World Health Organization criteria for the diagnosis of CEL are the presence of the cytogenetic alteration FIP1L1::PDGFRA as an oncogene; in its absence, morphological criteria in bone marrow define the diagnosis with blasts > 5% and < 20% and in peripheral blood with > 2% of blasts and eosinophilia >1.5 × 10 9 /L. The current study describes the case of a 60‐year‐old man who was admitted to the internal medicine department in critical condition with fever, cough, dyspnea, shortness of breath, and intense abdominal pain, and his spleen had the following measurements: 8‐8‐10 cm. The complete blood count showed hemoglobin 8.5 g/dL, platelets92 × 10 9 /L, leukocytes105.97 × 10 9 /L, total neutrophils31.79 × 10 9 /L, AEC69.40 × 10 9 /L, and lymphocytes4.23 × 10 9 /L, and the bone marrow analysis revealed 25% eosinophils and 12% myeloblasts. Thorax and abdomen computed tomography showed interstitial infiltrate, pleural effusion, and splenomegaly. Endoscopy showed ulcerative lesions in the digestive tract. This case underscores the crucial role of both bone marrow and peripheral blood morphological criteria in diagnosing CEL. This rare disease manifests at an advanced stage with complex clinical features but responds well to cytarabine.